Dyslipidemia, inflammation and dialysis outcomes: What we know now

Current Opinion in Nephrology and Hypertension

Volumn 15, Issue 6, 2006, Pages 566-570

  Krane, Vera ^a,b   Drechsler, Christiane ^a   Wanner, Christoph ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Dialysis; Dyslipidemia; Inflammation; Mortality; Outcome; Type 2 diabetes mellitus

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DYSLIPIDEMIA; HEMODIALYSIS; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; SYSTEMATIC REVIEW; VASCULAR DISEASE;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 33750213124     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000247501.41420.dd     Document Type: Review

References (27)

1. Eknoyan G, Beck GJ, Cheung AK, et al., Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010-2019.
2. Paniagua R, Amato D, Vonesh E, et al., Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13:1307-1320.
3. Holdaas H, Fellstrom B, Jardine AG, et al., Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361:2024-2031.
4. Wanner C, Krane V, Marz W, et al., German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238-248. This is the first large-scale, prospective, randomized, placebo-controlled trial testing the so far commonly accepted hypothesis that statin therapy in CKD patients is effective and safe. Against all expectations, it showed no significant reduction in the primary endpoint raising many questions about the type and character of cardiac and vascular disease in CKD patients and the associated causes of death. Simultaneously, it advises us to be cautious when extrapolating data from the general population to CKD patients and encourages us to get involved in clinical trials.
5. Shoji T, Ishizawa Y, Kawagishi T, et al. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis 1997; 131:229-236.
6. Attman P-O, Samuelsson O, Moberly J, et al. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 1999; 55:1536-1542.
7. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291:451-459.
8. Faraj M, Messier L, Bastard JP, et al. Apolipoprotein B: a predictor of inflammatory status in postmenopausal overweight and obese women. Diabetologia 2006; 49:1637-1646.
9. Cohn JS, Patterson BW, Uffelman KD, et al. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J Clin Endocrinol Metab 2004; 89:3949-3955.
10. Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000; 102:1886-1892.
11. Kawakami A, Aikawa M, Libby P, et al. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation 2006; 113:691-700. By discovering that increased levels of apolipoprotein CIII cause enhanced adhesion of inflammatory cells to endothelial cells via PKC- and RhoA-mediated beta 1 integrin activation, the authors demonstrate a direct interrelation between the special type of dyslipidemia in chronic kidney disease and inflammation.
12. Ruan XZ, Moorhead JF, Tao JL, et al. Mechanisms of dysregulation of low-density lipoprotein receptor expression in vascular smooth muscle cells by inflammatory cytokines. Arterioscler Thromb Vasc Biol 2006; 26:1150-1155.
13. Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 2003; 14:315-320.
14. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002; 61:1887-1893.
15. Zoccali C, Enia G, Tripepi G, et al. Clinical epidemiology of major nontraditional risk factors in peritoneal dialysis patients. Perit Dial Int 2005; 25:84-87.
16. Wanner C, Zimmermann J, Schwedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl 2002; 80:99-102.
17. Avram MM, Fein PA, Paluch MM, et al. Association between C-reactive protein and clinical outcomes in peritoneal dialysis patients. Adv Perit Dial 2005; 21:154-158.
18. Honda H, Qureshi AR, Heimburger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47:139-148.
19. Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14:2084-2091.
20. Stuveling EM, Hillege HL, Bakker SJ, et al. C-reactive protein is associated with renal function abnormalities in a nondiabetic population. Kidney Int 2003; 63:654-661.
21. Tonelli M, Sacks F, Pfeffer M, et al., Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005; 68:237-245. This post hoc subgroup analysis suggests that the loss of kidney function among subjects with chronic kidney disease and concomitant coronary disease may be mediated by inflammation.
22. Caravaca F, Martin MV, Barroso S, et al. Do inflammatory markers add predictive information of death beyond that provided by age and comorbidity in chronic renal failure patients? Nephrol Dial Transplant 2006; 21:1575-1581.
23. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44:6-11.
24. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105:2462-2464.
25. Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290:2945-2951.
26. Wanner C, Krane V, Marz W, et al., Deutsche Diabetes-Dialyse-Studie (4D) Study Group. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Press Res 2004; 27:259-266.
27. Fellstrom B, Zannad F, Schmieder R, et al., AURORA Study Group. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 2005; 6:9.